Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-iGRP78
- Development stage
- Preclinical
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[177Lu]Lu-iGRP78 is an experimental radiopharmaceutical designed for targeted radionuclide therapy, specifically for the treatment of castration-resistant prostate cancer. It consists of a ligand (iGRP78) that selectively binds to Glucose-Regulated Protein 78 (GRP78), which is chelated with the beta-emitting radioisotope lutetium-177. While GRP78 is primarily an endoplasmic reticulum chaperone, it is overexpressed on the cell surface (CS-GRP78) of various aggressive cancer cells. By targeting CS-GRP78, [177Lu]Lu-iGRP78 delivers localized ionizing radiation to tumor cells, causing DNA damage and subsequent apoptosis. In preclinical research, this monomeric agent is often evaluated as a component of bispecific radioligands, such as [177Lu]Lu-iPSMA-iGRP78, to enhance cellular internalization and therapeutic efficacy compared to monotherapy targeting PSMA alone.
- Other names
- Lutetium-177 iGRP78Lutetium177 iGRP78Lutetium 177 iGRP78[177Lu]-iGRP78
02
Targets
HSPA5 (Heat shock protein family A member 5)
Beyond the preview
Go deeper on [177Lu]Lu-iGRP78.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [177Lu]Lu-iGRP78.